BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu J, Smogorzewski J. Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases. Dermatol Ther 2021;34:e14883. [PMID: 33594811 DOI: 10.1111/dth.14883] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Miyagawa F. Pathogenesis of Paradoxical Reactions Associated with Targeted Biologic Agents for Inflammatory Skin Diseases. Biomedicines 2022;10:1485. [DOI: 10.3390/biomedicines10071485] [Reference Citation Analysis]
2 Marsal J, Barreiro-de Acosta M, Blumenstein I, Cappello M, Bazin T, Sebastian S. Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Front Med 2022;9:897936. [DOI: 10.3389/fmed.2022.897936] [Reference Citation Analysis]
3 Hosaka Y, Itoh K, Matsutani S, Kawate S, Miura A, Mizoura Y, Yamada S, Konno H, Grave E, Nagata K, Wakui H, Itoh H. Fermented food Tempeh induces interleukin 12 and enhances macrophage phagocytosis. J Food Biochem 2021;45:e13958. [PMID: 34611901 DOI: 10.1111/jfbc.13958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Westerdahl JS, Nusbaum KB, Chung CG, Kaffenberger BH, Ortega-Loayza AG. Ustekinumab as adjuvant treatment for all pyoderma gangrenosum subtypes. J Dermatolog Treat 2021;:1-5. [PMID: 34057010 DOI: 10.1080/09546634.2021.1937475] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]